✦ LIBER ✦

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

✍ Scribed by Raffi, François; Jaeger, Hans; Quiros-Roldan, Eugenia; Albrecht, Helmut; Belonosova, Elena; Gatell, Jose M; Baril, Jean-Guy; Domingo, Pere; Brennan, Clare; Almond, Steve; Min, Sherene

Book ID: 121288660
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 274 KB
Volume: 13
Category: Article
ISSN: 1473-3099
DOI: 10.1016/S1473-3099(13)70257-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-daily dolutegravir versus raltegrav

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

✍ Raffi, Francois; Rachlis, Anita; Stellbrink, Hans-Jürgen; Hardy, W David; Torti, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 368 KB

Dolutegravir versus raltegravir in antir

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

✍ Cahn, Pedro; Pozniak, Anton L; Mingrone, Horacio; Shuldyakov, Andrey; Brites, Ca 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 343 KB

Once-daily dolutegravir versus darunavir

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

✍ Clotet, Bonaventura; Feinberg, Judith; van Lunzen, Jan; Khuong-Josses, Marie-Aud 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 328 KB

Once daily dolutegravir (S/GSK1349572) i

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

✍ Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; B 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 204 KB

Efficacy and safety of once daily elvite

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

✍ Jean-Michel Molina; Anthony LaMarca; Jaime Andrade-Villanueva; Bonaventura Clote 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 209 KB

Ritonavir-boosted darunavir combined wit

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

✍ Raffi, François; Babiker, Abdel G; Richert, Laura; Molina, Jean-Michel; George, 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 395 KB